Juventas Therapeutics


Regenerative medicine company begins enrollment in critical limb ischemia trial

Regenerative medicine startup Juventas Therapeutics has begun enrollment in a phase 2a trial of critical limb ischemia patients. The Cleveland-based company, which recently secured an important investment from Takeda Pharmaceuticals, is planning to enroll 48 patients and complete enrollment early next year, CEO Rahul Aras said. Juventas’ technology, called JVS-100, works by recruiting stem cells […]


Regenerative medicine company encouraged by heart failure trial

Regenerative medicine company Juventas Therapeutics is touting the results from 12-month data of a phase 1 clinical trial of heart failure patients. At 12 months, heart failure patients treated with the company’s stem cell therapy showed “significant” improvements in two key measures — a six-minute distance-walking test, as well as the Minnesota Living with Heart […]


Juventas’ stem cell therapy shows promise in phase 1 study

A phase 1 clinical trial has shown that Juventas Therapeutics‘ regenerative medicine therapy provides clinical benefit to heart failure patients. Phase 1 trials generally focus on safety, so the indication of clinical benefit is an encouraging sign for Cleveland-based Juventas. “We are excited to see strong signs of efficacy across multiple clinical parameters,” CEO Rahul […]

presented by

Regenerative medicine startup Juventas completes phase 1 heart failure trial

Cleveland Clinic spinoff Juventas Therapeutics has successfully completed a phase 1 clinical trial of its regenerative medicine technology in heart failure patients. Cleveland-based Juventas’ technology, JVS-100, works by recruiting stem cells from the bone marrow to create new blood vessels. In addition to heart failure patients, the company is investigating the treatment of patients suffering […]


Cleveland Clinic Innovations starts next decade with 33 companies

Updated 4:36 p.m. Cleveland Clinic Innovations — the corporate venturing arm of the nation’s top heart  hospital — is entering its second decade with a first-of-its-kind venture ranking, a brand-new incubator building and a growing portfolio of spin-out companies. Perhaps most impressive, those companies — 33 in all — have attracted more than $340 million […]


Juventas Therapeutics starts Phase 1 trial for heart failure

Clinical-stage regenerative medicine company Juventas Therapeutics Inc.–a Cleveland Clinic spin-off initially named AccelleRX–has started enrolling patients in a Phase 1 clinical trial to evaluate the safety and efficacy of its leading stem cell factor for treating heart failure. In preclinical studies of heart failure in pigs, JVS-100, as the factor is known, significantly increased cardiac […]